指南与共识泌尿生殖妇产影像技术与安全MRPET

EAU 2026 前列腺癌指南:筛查、诊断与根治性局部治疗

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
指南 / 共识 · Eur Urol · 2026-07-15

本指南更新了欧洲泌尿外科学会等六大学会 2026 版前列腺癌筛查、诊断及局限性前列腺癌治疗建议。专家组系统回顾 2023 年 5 月至 2025 年英文文献,并为每条推荐赋予强度分级。核心内容包括风险适应性筛查策略、多参数磁共振减少不必要活检、靶向联合区域活检、五级 EAU 分级、PSMA PET 分期及主动监测指征。

要点

  • 推荐使用多参数磁共振成像以避免不必要的前列腺活检。
  • 需活检时,应联合靶向活检与区域活检。
  • PSMA PET 是识别转移灶最敏感的影像技术。

核心结论

  • 局限性前列腺癌的诊断、分期及治疗证据快速演变,本指南体现多学科管理特点。
  • 推荐风险适应性策略识别可能发展为前列腺癌的男性,一般从 50 岁开始并结合个体化预期寿命。

研究设计与样本

  • 由 EAU、EANM、ESTRO、ESUR、ISUP、SIOG 联合专家组制定。
  • 系统回顾 2023 年 5 月至 2025 年发表的全部英文文献,基于证据系统评价为每条推荐赋予强度等级。

关键影像表现/征象

  • 多参数磁共振成像用于避免不必要的前列腺活检。
  • 前列腺特异性膜抗原 PET 成像是识别转移性播散最敏感的技术。

诊断标准与关键数值

  • 引入新的五级 EAU 前列腺癌分类体系。
  • 需活检时推荐靶向活检联合区域活检。
  • 主动监测适用于低危前列腺癌及部分有利中危 ISUP 2 级病变。
  • 中危患者可考虑大分割放疗。
  • cN1 患者应接受原发灶放疗联合长期强化内分泌治疗。

临床应用与阅片要点

  • 阅片时应强调多参数磁共振在活检决策前的应用价值。
  • 报告前列腺病灶时应参照新的五级 EAU 分类进行描述。
  • PSMA PET 用于分期时,应关注其对转移灶的高敏感性。
  • 活检规划需覆盖靶向及区域部位,避免仅取靶向病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and treatment of clinically localised prostate cancer (PCa).

METHODS: The Panel performed a literature review of all new data published in English, covering the time frame between May 2023 and 2025. The Guidelines were updated, and a strength rating for each recommendation was added based on a systematic review of the evidence.

KEY FINDINGS: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. The use of multiparametric magnetic resonance imaging to avoid unnecessary biopsies is recommended. When a biopsy is considered, a combination of targeted and regional biopsies should be performed. A new five-tier EAU classification has been introduced. Prostate-specific membrane antigen positron emission tomography imaging is the most sensitive technique for identifying metastatic spread. Active surveillance is the appropriate management for men with low-risk PCa, as well as for patients with selected favourable intermediate-risk ISUP grade group 2 lesions. Local therapies are addressed, as well as the management of persistent prostate-specific antigen after surgery. A recommendation to consider hypofractionated radiotherapy in intermediate-risk patients is provided. Patients with cN1 PCa should be offered radiotherapy to the primary tumour combined with long-term intensified hormonal treatment.

CONCLUSIONS AND CLINICAL IMPLICATIONS: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. These PCa Guidelines reflect the multidisciplinary nature of PCa management.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Cornford, van den Bergh, Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2026. PMID: 42457454. doi:10.1016/j.eururo.2026.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。